CPB
24
2
GOOGL
59
-5
EXPE
96
5
BRK.B
40
2
A
41
-3
PVH
65
-3
DG
10
2
DNB
84
16
RF
66
3
KSS
39
-4
FIS
55
5
FOXA
66
2
MA
67
3
WU
22
2
GT
67
3
UNH
67
3
SYK
64
2
LOW
56
3
EMC
65
-12
VMC
65
2
CPB
24
2
GOOGL
59
-5
EXPE
96
5
BRK.B
40
2
A
41
-3
PVH
65
-3
DG
10
2
DNB
84
16
RF
66
3
KSS
39
-4
FIS
55
5
FOXA
66
2
MA
67
3
WU
22
2
GT
67
3
UNH
67
3
SYK
64
2
LOW
56
3
EMC
65
-12
VMC
65
2
Financhill
Back

Revance Therapeutics 10K Form

Sell
13

RVNC
Revance Therapeutics

Last Price:
3.71
Seasonality Move:
7.02%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RVNC News And Ratings

See the #1 stock for the next 7 days that we like better than RVNC

RVNC Financial Statistics

Sales & Book Value

Annual Sales: $234.04M
Cash Flow: $-38.14M
Price / Cash Flow: 0
Annual Sales: $-1.24
Price / Book: 0

Profitability

EPS (TTM): -3.20000
Net Income (TTM): $-287.5M
Gross Margin: $159.68M
Return on Equity: 0%
Return on Assets: -55.05%

Revance Therapeutics Earnings Forecast

Key Revance Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 13 years for RVNC is 68.23%.
  • The Selling, General & Administrative Expenses for RVNC have been equal to 124.87% of Gross Profit Margin.
  • The Research & Development expenses have been 33.93% of Revenue.
  • The Interest Expense is -5.97% of Operating Income.
  • The Net Earning history of RVNC is -138.43% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 6 years.

Revance Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: RVNC
CUSIP: 761330
Website: revance.com

Debt

Debt-to-Equity Ratio: -3.32
Current Ratio: 3.74
Quick Ratio: 2.87

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RVNC Technical Analysis vs Fundamental Analysis

Sell
13
Revance Therapeutics (RVNC) is a Sell

Is Revance Therapeutics a Buy or a Sell?